These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1571213)

  • 41. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary?
    Brandt LJ; Broadbent V
    Med Pediatr Oncol; 1993; 21(1):31-5. PubMed ID: 8426573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The use of holoxan (iphosphamide) in malignant tumors].
    Perevodchikova NI; Orel NF; Trofimova NV
    Vopr Onkol; 1990; 36(9):1085-8. PubMed ID: 2122594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
    Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children].
    Zielińska E; Zubowska M; Bodalski J
    Pol Merkur Lekarski; 2003 Apr; 14(82):295-8. PubMed ID: 12868187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal ontogeny of ifosfamide nephrotoxicity.
    Aleksa K; Halachmi N; Ito S; Koren G
    J Lab Clin Med; 2004 Dec; 144(6):285-93. PubMed ID: 15614250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
    Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
    Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nephrotoxicity after ifosfamide.
    Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
    Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Nephrotoxicity of ifosfamide with special reference to Fanconi Syndrome].
    Rogowska E; Woźniak W
    Med Wieku Rozwoj; 2004; 8(2 Pt 1):289-95. PubMed ID: 15738605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors.
    Arga M; Oguz A; Pinarli FG; Karadeniz C; Citak EC; Emeksiz HC; Duran EA; Soylemezoglu O
    Pediatr Int; 2015 Jun; 57(3):406-13. PubMed ID: 25441241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide.
    Köther M; Schindler J; Oette K; Berthold F
    In Vivo; 1992; 6(2):219-21. PubMed ID: 1525342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R; Cotterill SJ; Stevens MC
    Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.
    Agaliotis DP; Ballester OF; Mattox T; Hiemenz JW; Fields KK; Zorsky PE; Goldstein SC; Perkins JB; Rosen RM; Elfenbein GJ
    Am J Med Sci; 1997 Nov; 314(5):292-8. PubMed ID: 9365330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal function in children and adolescents following 72 g/m2 of ifosfamide.
    Arndt C; Morgenstern B; Wilson D; Liedtke R; Miser J
    Cancer Chemother Pharmacol; 1994; 34(5):431-3. PubMed ID: 8070011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
    Bokemeyer C; Fels LM; Dunn T; Voigt W; Gaedeke J; Schmoll HJ; Stolte H; Lentzen H
    Br J Cancer; 1996 Dec; 74(12):2036-41. PubMed ID: 8980410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
    Boddy AV; English M; Pearson AD; Idle JR; Skinner R
    Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug-induced nephrotoxicity in children: pharmacologically based prevention of long-term impairment.
    Koren G; Chen N; Aleksa K
    Paediatr Drugs; 2007; 9(3):139-42. PubMed ID: 17523693
    [No Abstract]   [Full Text] [Related]  

  • 59. Ifosfamide-induced alteration of technetium-99m-DMSA renal parenchymal imaging.
    Morrison SC; O'Donnell JK
    J Nucl Med; 1997 Nov; 38(11):1811-2. PubMed ID: 9374361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
    Caglar K; Kinalp C; Arpaci F; Turan M; Saglam K; Ozturk B; Komurcu S; Yavuz I; Yenicesu M; Ozet A; Vural A
    Nephrol Dial Transplant; 2002 Nov; 17(11):1931-5. PubMed ID: 12401849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.